Abstract
Oltipraz, which has been extensively studied as a cancer chemopreventive agent, promotes phosphatidylinositol 3-kinase-mediated activation of CCAAT/enhancer binding protein-β (C/EBPβ). Activated p90 ribosomal S6-kinase-1 (RSK1) phosphorylates major transcription factors, including C/EBPβ. This study examined whether oltipraz induces phosphorylation of C/EBPβ at specific residues, and if so, whether RSK1 regulates C/EBPβ phosphorylation by oltipraz for the GSTA2 gene transactivation. Subcellular fractionation and immunoblot analyses revealed that oltipraz treatment increased the level of C/EBPβ phosphorylated at Ser105 in the cytoplasm, which translocated to the nucleus for DNA binding in rat H4IIE cells. Immunoprecipitation-immunoblot, chromatin-immunoprecipitation, and specific mutation analyses revealed that Ser105-phosphorylated C/EBPβ recruited the cAMP response element-binding protein binding protein for histone acetylation and transactivation of the GSTA2 gene. The role of RSK1 in Ser105-phosphorylation of C/EBPβ by oltipraz and its gene transactivation was evidenced by transfection experiments with dominant-negative mutants of RSK1. In mouse Hepa1c1c, human HepG2 cells, and rat primary hepatocytes, oltipraz induced phosphorylation of C/EBPβ at Thr217, Thr266, and Ser105, respectively, via RSK1. The experiment using small-interference RNA of RSK1 confirmed the essential role of RSK1 in the gene expression. Inhibition of PI3-kinase activity prevented oltipraz-inducible Ser105-phosphorylation of rat C/EBPβ. Oltipraz treatment led to increases in the catalytic activity and nuclear translocation of RSK1, which was abrogated by PI3-kinase inhibition. In summary, oltipraz induces the phosphorylation of rat C/EBPβ at Ser105 (functionally analogous Thr217/266 in mouse and human forms) in hepatocytes, which results in cAMP response element-binding protein-binding protein (CBP) recruitment for the GSTA2 gene transactivation, and the specific C/EBPβ phosphorylation is mediated by RSK1 downstream of PI3-kinase.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|